Value of palliative resection in gastric cancer
- PMID: 12390389
- DOI: 10.1046/j.1365-2168.2002.02220.x
Value of palliative resection in gastric cancer
Abstract
Background: Western patients with gastric cancer often present with incurable disease. The role of palliative surgical resection is still debatable. Non-curatively treated patients from the Dutch Gastric Cancer Trial were studied to define more accurately which patients might benefit from palliative resection.
Methods: In the Dutch Gastric Cancer Trial 285 (26 per cent) of the randomized patients were found to have incurable tumours at laparotomy. Four signs of incurability were noted: irresectable tumour (T+), hepatic metastasis (H+), peritoneal metastasis (P+) and distant lymph node metastasis (N4+). Patients had either an explorative laparotomy, a gastroenterostomy, or a resection (partial or total). In the analysis, particular attention was paid to the prognostic factors of age, number of metastatic features, and a combination of these.
Results: Overall survival time was greater if a resection was performed (8.1 versus 5.4 months; P < 0.001). For patients aged over 70 years there was still a survival advantage of about 3 months if resection was carried out. Morbidity and perioperative mortality rates in this older age group were, however, high (50 and 20 per cent respectively). For patients with one metastatic site a resection was of significant benefit (survival 10.5 versus 6.7 months; P = 0.034). For patients with two or more metastatic sites resection had no significant survival advantage (5.7 versus 4.6 months; P = 0.084). Combination of these factors indicates that patients aged less than 70 years with one metastatic site will benefit significantly from a palliative resection, in contrast to other combinations of factors.
Conclusion: Age as well as the number of metastatic sites should be taken into account when a palliative resection is considered. Palliative resection may be beneficial for patients under 70 years of age if the tumour load is restricted to one metastatic site.
Similar articles
-
Results following resection for stage IV gastric cancer; are better outcomes observed in selected patient subgroups?J Surg Oncol. 2007 Feb 1;95(2):118-22. doi: 10.1002/jso.20328. J Surg Oncol. 2007. PMID: 17262741
-
Palliative gastrectomy in advanced gastric cancer: is it worthwhile?ANZ J Surg. 2006 Jan-Feb;76(1-2):60-3. doi: 10.1111/j.1445-2197.2006.03649.x. ANZ J Surg. 2006. PMID: 16483298
-
Tumor load and surgical palliation in gastric cancer.Hepatogastroenterology. 2001 Sep-Oct;48(41):1219-21. Hepatogastroenterology. 2001. PMID: 11677934 Clinical Trial.
-
Does the surgical stress associated with palliative resection for patients with incurable gastric cancer with distant metastasis shorten their survival?Hepatogastroenterology. 2004 May-Jun;51(57):872-5. Hepatogastroenterology. 2004. PMID: 15143937
-
Does surgery have a role in managing incurable gastric cancer?Nat Rev Clin Oncol. 2015 Nov;12(11):676-82. doi: 10.1038/nrclinonc.2015.132. Epub 2015 Aug 11. Nat Rev Clin Oncol. 2015. PMID: 26260039 Review.
Cited by
-
PALLIATIVE GASTRECTOMY VERSUS GASTRIC BYPASS FOR SYMPTOMATIC CLINICAL STAGE IV GASTRIC CANCER: A PROPENSITY SCORE MATCHING ANALYSIS.Arq Bras Cir Dig. 2024 Feb 5;36:e1790. doi: 10.1590/0102-672020230072e1790. eCollection 2024. Arq Bras Cir Dig. 2024. PMID: 38324851 Free PMC article.
-
[Endoscopic palliation of malignant gastric outlet obstruction by self-expanding metal stents].Wien Klin Wochenschr. 2003 Dec 15;115(23):840-5. doi: 10.1007/BF03041045. Wien Klin Wochenschr. 2003. PMID: 14740348 German.
-
Follow-up of gastric cancer: a review.Gastric Cancer. 2006;9(2):74-81. doi: 10.1007/s10120-006-0360-0. Gastric Cancer. 2006. PMID: 16767361 Review.
-
Survival benefit of non-curative gastrectomy for gastric cancer patients with synchronous distant metastasis.J Gastrointest Surg. 2010 Feb;14(2):282-8. doi: 10.1007/s11605-009-1095-0. Epub 2009 Nov 25. J Gastrointest Surg. 2010. PMID: 19937478
-
Advances in Treatment Models of Advanced Gastric Cancer.Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221090353. doi: 10.1177/15330338221090353. Technol Cancer Res Treat. 2022. PMID: 36780331 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical